Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

$FULC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $FULC alert in real time by email
SC 13G/A 1 tm2422355d2_sc13ga.htm SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 3)*

 

Fulcrum Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

359616109

(CUSIP Number)

 

August 21, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
xRule 13d-1(c)
¨Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No.   359616109
1

Names of Reporting Persons
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

RA Capital Management, L.P.

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨

(b) ¨

 

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

Delaware

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

Sole Voting Power

 

0

 

6

Shared Voting Power

 

5,544,216

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

5,544,216

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,544,216

 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11

Percent of Class Represented by Amount in Row (9)

 

9.99%

 

12

Type of Reporting Person (See Instructions)

 

IA, PN

 

 

 

 

 

CUSIP No.   359616109
1

Names of Reporting Persons
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Peter Kolchinsky

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨

(b) ¨

 

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

Sole Voting Power

 

0

 

6

Shared Voting Power

 

5,544,216

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

5,544,216

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,544,216

 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11

Percent of Class Represented by Amount in Row (9)

 

9.99%

 

12

Type of Reporting Person (See Instructions)

 

HC, IN

 

 

 

 

 

CUSIP No.   359616109
1

Names of Reporting Persons
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Rajeev Shah

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨

(b) ¨

 

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

Sole Voting Power

 

0

 

6

Shared Voting Power

 

5,544,216

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

5,544,216

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,544,216

 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11

Percent of Class Represented by Amount in Row (9)

 

9.99%

 

12

Type of Reporting Person (See Instructions)

 

HC, IN

 

 

 

 

CUSIP No.   359616109
1

Names of Reporting Persons
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

RA Capital Healthcare Fund, L.P.

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨

(b) ¨

 

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

Delaware

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

Sole Voting Power

 

0

 

6

Shared Voting Power

 

5,544,216

 

7

Sole Dispositive Power

 

0

 

8

Shared Dispositive Power

 

5,544,216

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,544,216

 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11

Percent of Class Represented by Amount in Row (9)

 

9.99%

 

12

Type of Reporting Person (See Instructions)

 

PN

 

 

 

 

 

Item 1(a).Name of Issuer:
  
 Fulcrum Therapeutics, Inc. (the “Issuer”)

 

Item 1(b).Address of Issuer’s Principal Executive Offices:
  
 26 Landsdowne Street, Cambridge, MA 02139

 

Item 2(a).Names of Persons Filing:
  
 The names of the persons filing this report (collectively, the “Reporting Persons”) are:
  
 RA Capital Management, L.P. (“RA Capital”)
 Peter Kolchinsky
 Rajeev Shah
 RA Capital Healthcare Fund, L.P. (the “Fund”)

 

Item 2(b).Address of Principal Business Office or, if None, Residence:
  
 The address of the principal business office of each of the Reporting Persons is:
  
 c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

 

Item 2(c).Citizenship:
  
 RA Capital and the Fund are Delaware limited partnerships.
 Dr. Kolchinsky and Mr. Shah are United States citizens.

 

Item 2(d).Title of Class of Securities:
  
 Common Stock, par value $0.001 per share (“Common Stock”)

 

Item 2(e).CUSIP Number:
  
 359616109

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
  
 Not applicable.

 

Item 4.Ownership.
  
 The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The ownership percentages reported are based upon the sum of (i) 53,063,149 shares of Common Stock outstanding as of August 22, 2024, as disclosed to the Reporting Persons by the Issuer and (ii) 2,434,512 Common Shares issuable upon the exercise of Pre-Funded Warrants (as defined below).
  
 The Fund directly holds 3,109,704 shares of Common Stock and pre-funded warrants (“Pre-Funded Warrants”) exercisable for up to 8,500,000 shares of Common Stock. The Pre-Funded Warrants contain a provision (the “Beneficial Ownership Blocker”), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 5,544,216 shares of Common Stock.

 

 

 

 

 RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

 

Item 5.Ownership of Five Percent or Less of a Class.
  
 If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.
  
 Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
  
 Not applicable.

 

Item 8.Identification and Classification of Members of the Group.
  
 Not applicable.

 

Item 9.Notice of Dissolution of Group.
  
 Not applicable.

 

Item 10.Certification.
  
 By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

Exhibit List

 

Exhibit 1:           Joint Filing Agreement

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: August 23, 2024

 

RA CAPITAL MANAGEMENT, L.P.  
   
By: /s/ Peter Kolchinsky  
  Name: Peter Kolchinsky  
  Title: Authorized Signatory  
   
PETER KOLCHINSKY  
   
/s/ Peter Kolchinsky  
   
RAJEEV SHAH  
   
/s/ Rajeev Shah  
   
RA CAPITAL HEALTHCARE FUND, L.P.  
   
By: RA Capital Healthcare Fund GP, LLC  
Its: General Partner  
   
By: /s/ Peter Kolchinsky  
  Name: Peter Kolchinsky  
  Title: Manager  

 

 

 

Get the next $FULC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FULC

DatePrice TargetRatingAnalyst
9/13/2024$17.00 → $4.00Buy → Neutral
H.C. Wainwright
9/12/2024$15.00 → $4.00Outperform → Sector Perform
RBC Capital Mkts
9/12/2024$4.00Outperform → Market Perform
Leerink Partners
9/12/2024$10.00 → $2.00Neutral → Underperform
BofA Securities
9/12/2024Buy → Hold
Stifel
9/12/2024Overweight → Neutral
Cantor Fitzgerald
9/9/2024$5.00 → $10.00Underperform → Neutral
BofA Securities
5/20/2024$23.00Overweight
Cantor Fitzgerald
More analyst ratings

$FULC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

    CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET. The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

    ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quart

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

    CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive di

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FULC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FULC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FULC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FULC
SEC Filings

See more

$FULC
Leadership Updates

Live Leadership Updates

See more
  • Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics Appoints Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FULC
Financials

Live finance-specific insights

See more
  • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

    ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quart

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

    CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive di

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

    ― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2024 as well as a business update. "In the third

    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FULC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more